Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Aldoxorubicin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LadRx Planning NDA Submission for Aldoxorubicin & Updates
    LadRx Planning NDA Submission for Aldoxorubicin & Updates

    11 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241211915887/en

    BUSINESSWIRE
    11 Dec 2024
    Share Share
    LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
    LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603328713/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Various Forms of Cancer
    CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Various Forms of Cancer

    21 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211221005233/en

    BUSINESSWIRE
    21 Dec 2021
    Share Share
    CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding
    CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding

    15 Jan 2021

    // NEWS

    https://in.news.yahoo.com/cytrx-highlights-aldoxorubicin-phase-2-130000215.html

    NEWS
    15 Jan 2021
    Share Share
    CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive
    CytRx Highlights Use of Aldoxorubicin in Ph 2 Clinical Trials Yielding Positive

    15 Jan 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210115005117/en

    BUSINESSWIRE
    15 Jan 2021
    Share Share
    CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph2 Study
    CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Ph2 Study

    12 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201013005364/en

    BUSINESSWIRE
    12 Oct 2020
    Share Share